Loading...
Date of Award
Spring 2024
Degree Name
Master of Medical Science (Physician Assistant)
Department
Physician Assistant; College of Health Sciences
First Advisor
Michelle Thal
Abstract
Even with a well-established treatment regimen, asthma is very prevalent and is continuously morphing. Step therapy is a generalized guideline for managing asthma but is not based on the pathophysiology of its subtypes. Currently, biological agents (also called monoclonal antibodies) are indicated for severe persistent asthma attacks. They are designed to target mechanisms of action and pathways to elicit an effect. This article explores the use of Omalizumab and Mepolizumab in comparison to one another. Both agents have indications for practicality of using biological agents given accessibility, cost, and the widespread presence of asthma.
Recommended Citation
Thotakura, Neha, "A Comparison of Omalizumab and Mepolizumab in Severe Asthma" (2024). Capstone Showcase. 33.
https://scholarworks.arcadia.edu/showcase/2024/pa/33
A Comparison of Omalizumab and Mepolizumab in Severe Asthma
Even with a well-established treatment regimen, asthma is very prevalent and is continuously morphing. Step therapy is a generalized guideline for managing asthma but is not based on the pathophysiology of its subtypes. Currently, biological agents (also called monoclonal antibodies) are indicated for severe persistent asthma attacks. They are designed to target mechanisms of action and pathways to elicit an effect. This article explores the use of Omalizumab and Mepolizumab in comparison to one another. Both agents have indications for practicality of using biological agents given accessibility, cost, and the widespread presence of asthma.